LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Closed

SectorHealthcare

219.84 -1.36

Buy Sell

Overview

Share price change

24h

Current

Min

213.71

Max

223.33

Key metrics
By Trading Economics
Income	-22M -61M
Sales	56M 214M
Profit margin	-28.549
Employees	1,017
EBITDA	-56M -53M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+24.79% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1.7B 14B
Previous open	221.2
Previous close	219.84

News Sentiment

By Acuity

54%

46%

270 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 lut 2026, 23:47 UTC

Hot Stocks

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 lut 2026, 22:59 UTC

Earnings

Acquisitions, Mergers, Takeovers

Grab Holdings to Buy U.S.-Based Stash Financial

11 lut 2026, 23:54 UTC

Earnings

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 lut 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

11 lut 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 lut 2026, 23:49 UTC

Earnings

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 lut 2026, 23:45 UTC

Earnings

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 lut 2026, 23:42 UTC

Earnings

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 lut 2026, 23:41 UTC

Earnings

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 lut 2026, 23:40 UTC

Earnings

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 lut 2026, 23:35 UTC

Market Talk

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 lut 2026, 23:18 UTC

Market Talk

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 lut 2026, 23:14 UTC

Market Talk

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 lut 2026, 22:59 UTC

Earnings

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 lut 2026, 22:59 UTC

Earnings

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 lut 2026, 22:59 UTC

Earnings

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 lut 2026, 22:58 UTC

Earnings

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 lut 2026, 22:57 UTC

Earnings

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 lut 2026, 22:54 UTC

Earnings

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 lut 2026, 22:53 UTC

Earnings

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 lut 2026, 22:47 UTC

Earnings

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 lut 2026, 22:47 UTC

Earnings

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 lut 2026, 22:23 UTC

Earnings

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 lut 2026, 22:22 UTC

Earnings

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 lut 2026, 22:22 UTC

Earnings

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 lut 2026, 22:19 UTC

Earnings

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 lut 2026, 22:18 UTC

Earnings

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 lut 2026, 22:18 UTC

Earnings

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 lut 2026, 22:18 UTC

Earnings

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 lut 2026, 22:16 UTC

Earnings

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

24.79% upside

12 Months Forecast

Average 277.08 USD 24.79%

High 342 USD

Low 240 USD

Based on 13 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

270 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.